Panagiotis Vlachostergios, M.D., Ph.D.
< Back to Search Results

Panagiotis Vlachostergios, M.D., Ph.D.


Profile Photo of Panagiotis Vlachostergios, M.D., Ph.D.
Accepts New Patients
Gender: Male
Language: English, Greek


Specialties and Expertise


  • Hematology and Oncology


  • Prostate Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Testicular Cancer

Personal Statement

I have a broad background in translational and clinical cancer research, and a PhD in cancer biology. Since the beginning of my hematology and medical oncology training, I have cared for several patients afflicted with genitourinary cancers, including prostate, bladder, kidney and testicular cancers. I feel privileged and honored to have joined the faculty at Weill Cornell. Together with renowned mentors and colleagues in medical and urologic oncology, we work to offer the highest level of expertise and oncologic care to our patients. In parallel, my ongoing clinical research is focused on two main areas: 1) investigating the molecular changes of tumors as a means to design new targeted therapies 2) studying the impact of cancer-predisposing genes on the clinical course and treatment response of patients with advanced genitourinary cancers to improve genetic cancer risk assessment and counseling for these patients and their families.


Dr. Panagiotis J. Vlachostergios is an Assistant Professor of Clinical Medicine at Weill Cornell Medicine and an Assistant Attending in the Division of Hematology & Medical Oncology at NewYork-Presbyterian Brooklyn Methodist Hospital.

Dr. Vlachostergios holds a PhD degree in cancer biology and completed his residency training at the New York University School of Medicine, Brooklyn Campus. He completed his Hematology and Medical Oncology Fellowship at Weill Cornell Medicine, and received additional clinical and translational research training in the Weill Cornell Clinical and Translational Investigation post-graduate education program. During this time, he led studies on the molecular biology of upper tract urothelial carcinoma, and on genetic and genomic biomarkers in urothelial and prostate cancer patients treated with established (platinum) and investigational therapies (PSMA radioimmunotherapy), respectively.

Dr. Vlachostergios is an active member of the Clinical Cancer Genomics Community of Practice, having completed training in cancer genetic risk assessment by the City of Hope Division of Clinical Cancer Genomics. As a medical oncologist and clinical researcher, Dr. Vlachostergios conducts research focusing on understanding the genetics of early and advanced prostate and urothelial bladder cancers, as well as how these gene profiles can predict patient outcomes and sensitivity to current and novel therapies. Dr. Vlachostergios aims to identify heritable and acquired molecular alterations that can be exploited to better predict the clinical course of urological malignancies, and to develop more effective therapies and cancer prevention strategies for patient families, tailored to their individual genetic profiles. He is a co-investigator and co-principal investigator in numerous clinical trials conducted by the Weill Cornell Genitourinary Oncology program.

Dr. Vlachostergios has published several articles in peer-reviewed journals such as Nature Communications, Nature Reviews in Clinical Oncology, Seminars in Cancer Biology, Journal of National Comprehensive Cancer Network, Molecular Cancer Therapeutics, Journal of Oncology Practice, EMBO Molecular Medicine. Additionally, he is a reviewer for several journals including Prostate Cancer and Prostatic Diseases, Public Library of Science Medicine, Nature Cell Death and Disease, Oncotarget, Public Library of Science One. Dr. Vlachostergios is an editorial board member of several peer-reviewed journals, including Annals of Hematology and Oncology, Open Cancer Immunology journal, Clinical Cancer Drugs, Journal of Cancer Research and Treatment.

Honors and Awards

Honors and Awards

Dr. Vlachostergios is the recipient of several research awards, including the ASCO Conquer Cancer Foundation Merit Award (2018 and 2019), the Scott-Wadler Fellow Clinical Research award (2018 and 2019), the Rising Star in Oncology Award by the Society for Translational Oncology (2018), the John Quale Travel Fellowship Award by the Bladder Cancer Advocacy Network (2018), the Charles, Lilian and Betty Neuwirth Foundation Fellowship in Oncology Award (2018) and the Henry Christian Award by the American Federation for Medical
Research (2015).


Education and Training

  • Ph.D., University of Thessaly Faculty of Medicine (Greece), 2013
  • M.D., University of Thessaly Faculty of Medicine (Greece), 2007


Insurance Plans Accepted

For relevant information regarding accepted insurances, please contact this provider directly.

Locations and Appointments